Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

Peng, Qingsheng; Zhou, Run; Wang, Yuewen; Zhao, Mengxia; Liu, Na; Li, Shuang; Huang, Haode; Yang, Dawei; Au, Ka‐Kit; Wang, Hui; Man, Kwan; Yuen, Kwok‐Yung; Chen, Zhiwei

doi:10.1016/j.ebiom.2022.103904

Cited by 104 publications

(119 citation statements)

References 53 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…However, in kidney transplant recipients, mRNA based BNT162b2 has been shown to induce a higher nucleocapsid antibody response and T cell response than the inactivated vaccine, CoronoVac [17] . Also, the antibody response persists longer in BNT162b2 and is more effective against the omicron variant than the CoronoVac in healthy population [18] . On the other hand, in another study no antibody response was detected in 51.4% of the patients, despite four doses of the BNT162b2 vaccine in kidney transplant recipients [19] .…”

Section: Discussionmentioning

confidence: 97%

Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients

Demir¹,

Dheir²,

Şafak³

et al. 2022

Vaccine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients

Demir¹,

Dheir²,

Şafak³

et al. 2022

Vaccine

View full text Add to dashboard Cite

“…24 Moreover, a recent study of humoral and cellular responses among Hong Kong vaccinees over time found that neutralising antibodies against variants of concern dropped to detection limit only three months after vaccinations, along with diminishing memory T cell responses, primarily among CoronaVac recipients. 39 Our study has a number of limitations arising from available data and the nature of the epidemic within Hong Kong. Firstly, we used census data from the correct time period to construct the source population, but any differential population movement by vaccine status over the duration of the vaccination program could affect the validity of our estimates.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong

McMenamin

Nealon

Lin

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Hong Kong maintained extremely low circulation of SARS-CoV-2 until a major community epidemic of Omicron BA.2 starting in January 2022. Both mRNA BNT162b2 (BioNTech/Fosun Pharma) and inactivated CoronaVac (Sinovac) vaccines are widely available, however coverage has remained low in older adults. Vaccine effectiveness in this predominantly infection-naive population is unknown. Methods: We used individual-level case data on mild/moderate, severe/fatal and fatal hospitalized COVID-19 from December 31, 2021 to March 8, 2022, along with census information and coverage data of BNT162b2 and CoronaVac. We used a negative binomial model, adjusting for age and calendar day to estimate vaccine effectiveness of one, two and three dose schedules of both vaccines, and relative effectiveness by number of doses and vaccine type. Findings: A total of 12.7 million vaccine doses were administered in the 7.3 million population of Hong Kong, and we analyzed data from confirmed cases with mild/moderate (N=5,474), severe/fatal (N=5,294) and fatal (N=4,093) COVID-19. Two doses of either vaccine protected against severe disease and death, with higher effectiveness among adults ≥60 years with BNT162b2 (VE: 88.2%, 95% confidence interval, CI: 84.4%, 91.1%) compared to CoronaVac (VE: 74.1%, 95% CI: 67.8%, 79.2%). Three doses of either vaccine offered very high levels of protection against severe outcomes (VE: 98.1%, 95% CI: 97.1%, 98.8%). Interpretation: Third doses of either BNT162b2 or CoronaVac provide substantial additional protection against severe COVID-19 and should be prioritized, particularly in older adults who received CoronaVac primary schedules. Longer follow-up is needed to assess persistence of different vaccine platforms and schedules.

show abstract

“…showed that there is waning of humoral and T cell immunity at three months after the second dose of vaccination for both BNT162b2 and CoronaVac among individuals without prior infection. 54 Further studies are required to assess waning of immunity for vaccinees with prior infection. Third, we do not know the virus lineage causing the infection in these recovered individuals.…”

Section: Discussionmentioning

confidence: 99%

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines

Chen

Zhang

et al. 2022

eBioMedicine

Self Cite

View full text Add to dashboard Cite

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

Cited by 104 publications

References 53 publications

Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients

Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients

Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines

Contact Info

Product

Resources

About